New insights into the site and mode of antinociceptive action of flurbiprofen enantiomers

Journal of Clinical Pharmacology

Volumn 36, Issue 6, 1996, Pages 513-520

  Geisslinger, Gerd ^a,c   Schaible, Hans Georg ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Dept Exp Clin Pharmacol Toxicol ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLURBIPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SALICYLIC ACID;

ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENANTIOMER; ENZYME INHIBITION; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PAIN; POSTOPERATIVE PAIN; PROSTAGLANDIN SYNTHESIS INHIBITION; RACEMIC MIXTURE; RAT; RHEUMATOID ARTHRITIS;

EID: 0030055160     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb05041.x     Document Type: Conference Paper

References (85)

1. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-235.
2. Ferreira SH: Prostaglandins, aspirin-like drugs and analgesia. Nature 1972;240:200-203.
3. 2) and 6-oxo-PGF1α in the rat paw. Prostaglandins 1978;16:153-162.
4. Ferreira SH: Inflammatory pain, prostaglandin hyperalgesia and the development of peripheral analgesics. Trends Pharmacol Sci 1981;2:183-186.
5. Taiwo YO, Levine JD: Prostaglandin effects after elimination of indirect hyperalgesic mechanisms in the skin of the rat. Brain Res 1989;492:397-399.
6. 2α to conscious mice. Brain Res 1990;510:26-32.
7. 2 to mice. Br J Pharmacol 1994;112:735-740.
8. Mizumura K, Sato J, Kumazawa T: Effects of prostaglandins and other putative chemical intermediaries on the activity of canine testicular polymodal receptors studied in vitro. Pflügers Arch 1987;408:565-572.
9. Rueff A, Dray A: Sensitization of peripheral afferent fibers in the in vitro neonatal rat spinal cord-tail preparation by bradykinin and prostaglandins. Neuroscience 1993;54:527-535.
10. 2. J Physiol (Lond) 1988;403:91-104.
11. 2 in the sensitization of mechanoreceptors in normal and inflamed ankle joints of the rat. Exp Brain Res 1991;84:383-392.
12. 2. Neuroscience 1992;50:237-247.
13. Glatt M, Peskar B, Brune K: Leucocytes and prostaglandins in acute inflammation. Experientia 1974;30:1257-1259.
14. Kuehl FA, Egan RW: Prostaglandins, arachidonic acid, and inflammation. Science 1980;210:978-984.
15. Higgs GA, Moncada S, Salmon JA, Seager K: The source of thromboxane and prostaglandins in experimental inflammation. Br J Pharmacol 1983;79:863-868.
16. Salmon JA, Higgs GA: Prostaglandins and leukotrienes as inflammatory mediators. Br Med Bull 1987;43:285-296.
17. Vane JR, Botting R: Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987;1:89-96.
18. Garcia-Rafanell J, Forn J: Correlation between anti-inflammatory activity and inhibition of prostaglandin biosynthesis induced by various non-steroidal anti-inflammatory agents. Drug Res 1979;29:630-633.
19. Graham GG, Champion GD, Day RO, Kaski AL, Hills LG, Paull PD: Salicylates in rheumatoid arthritis: pharmacokinetics and analgesic response. Agents Actions Suppl 1977;7:37-42.
20. McCormack K, Brune K: Dissociation between the antinociceptive and anti-inflammatory effects of the non-steroidal anti-inflammatory drugs. Drugs 1991;41:533-547.
21. Brune K, Beck WS, Geisslinger G, Menzel-Soglowek S, Peskar BM, Peskar BA: Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. Experientia 1991;47:257-261.
22. Adams SS, Bresloff P, Mason CG: Pharmacological differences between the optical isomers of ibuprofen: evidence for metabolic inversion of the (-)-isomer. J Pharm Pharmacol 1976;28:256-257.
23. Geisslinger G, Stock K-P, Bach GL, Loew D, Brune K: Pharmacological differences between R(-)- and S(+)-ibuprofen. Agents Actions 1989;27:455-457.
24. Panara MR, Greco A, Santini G, Sciulli MG, Rotondo MT, Padovano R, et al: Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothiophenyl)-1-indanone (L-745,337), on the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmacol 1995;116:2429-2434.
25. Brune K, Geisslinger G, Menzel-Soglowek S: Pure enantiomers of 2-arylpropionic acids: tools in pain research and improved drugs in rheumatology. J Clin Pharmacol 1992;32:944-952.
26. Gryglewski RJ: Screening and assessment of the potency of antiinflammatory drugs in vitro. In, Vane JR, Ferreira SH (eds.): Antiinflammatory Drugs. Berlin: Springer Verlag, 1979;3-43.
27. Peskar BM, Kluge S, Peskar BA, Menzel-Soglowek S, Brune K: Effects of pure enantiomers of flurbiprofen in comparison to racemic flurbiprofen on eicosanoid release from various rat organs ex vivo. Prostaglandins 1991;42:515-531.
28. Menzel-Soglowek S, Geisslinger G, Beck WS, Brune K: Variability of inversion of (R)-flurbiprofen in different species. J Pharm Sci 1992;81:888-891.
29. Jamali F, Berry BW, Tehrani MR, Russell AS: Stereoselective pharmacokinetics of flurbiprofen in humans and rats. J Pharm Sci 1988;77:666-669.
30. Hemler M, Lands WEM, Smith WL: Purification of the cyclooxygenase that forms prostaglandins: demonstration of two forms of iron in the holoenzyme. J Biol Chem 1976;251:5575-5579.
31. Miyamoto T, Ogino N, Yamamoto S, Hayaishi O: Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1976;251:2629-2636.
32. Van der Ouderaa FJ, Buytenhek M, van Dorp DA: Purification and characterization of prostaglandin endoperoxide synthetase from sheep vesicular gland. Biochim Biophys Acta 1977;487:315-331.
33. DeWitt DL, Meade EA: Serum and glucocorticoid regulation of gene transcription and expression of the prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes. Arch Biochem Biophys 1993;306:94-102.
34. Merlie JP, Fagan D, Mudd J, Needleman P: Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 1988;263:3550-3553.
35. Simmons DL, Xie W, Chipman JG, Evett GE: Multiple cyclooxygenases: cloning of a mitogen-inducible form. In, Bailey J (ed.): Prostaglandins, Leukotrienes, Lipoxins, and PAF. New York: Plenum Press, 1991;67-78.
36. Vane J: Towards a better aspirin. Nature 1994;367:215-216.
37. Xie W, Chipman JG, Robertson DL, Erickson RL, Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-2696.
38. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxy-genase homologue. J Biol Chem 1991;266:12866-12872.
39. DeWitt DL: Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1991;1083:121-134.
40. Seibert K, Masferrer J: Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994;94:17-23.
41. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P: The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1989;265:16737-16740.
42. Masferrer JL, Reddy ST, Zweifel BS, Needleman P, Gilbert RS, Herschman HR: In vivo regulation of cyclooxygenase-2 but not cyclooxygenase-1 by glucocorticoids in peritoneal macrophages. J Pharmacol Exp Ther 1994;270:1340-1344.
43. Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk CD, Smith WL: Differential inhibition of human prostaglandin endoperoxide H synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-934.
44. Grossman CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ: Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX-2 inhibitors. Inflamm Res 1995;44:253-257.
45. Wechter WJ, Loughead DG, Reischer RJ, van Giessen GJ, Kaiser DG: Enzymatic inversion at the saturated carbon: nature and mechanism of the inversion of R(-)-p-iso-butyl hydrotropic acid. Biochem Biophys Res Commun 1974;61:833-837.
46. Hutt AJ, Caldwell J: The metabolic chiral inversion of 2-aryl-propionic acids: a novel route with pharmacological consequences. J Pharm Pharmacol 1983;35:693-704.
47. Williams KM: Enantiomers in arthritic disorders. Pharmacol Ther 1990;46:273-295.
48. Jamali F: Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs. Eur J Drug Metab Pharmacokinet 1988;13:1-9.
49. Wechter WJ: On the mechanism of R-arylpropionic acid class NSAIDs: epimerization in humans and the clinical implications for the use of racemates. J Clin Pharmacol 1994;34:1036-1042.
50. Menzel S, Waibel R, Brune K, Geisslinger G: Is the inversion of R-ibuprofenyl-adenylate the first stereoselective step of chiral inversion? Biochem Pharmacol 1994;48:1056-1058.
51. Nakamura Y, Yamaguchi T, Takahashi S, Hashimoto S, Iwatani K, Nakagawa Y: Optical isomerization mechanism of R(-)-hydratropic acid derivatives (abstract). J Pharmacobiodyn 1981;4: S-1.
52. Tracy TS, Wirthwein DP, Hall SD: Metabolic inversion of (R)-ibuprofen: formation of ibuprofenyl-coenzyme A. Drug Metab Dispos 1993;21:114-120.
53. Porubek DJ, Sanins SM, Stephens JR, Grillo MP, Kaiser DG, Halstead GW, et al: Metabolic chiral inversion of flurbiprofen-CoA in vitro. Biochem Pharmacol 1991;42:R1-R4.
54. Shieh WR, Chen CS: Purification and characterization of novel "2-arylpropionyl-CoA epimerases" from rat liver cytosol and mitochondria. J Biol Chem 1993;268:3487-3493.
55. Reichel C, Bang H, Brune K, Geisslinger G, Menzel S: 2-aryl-propionyl-CoA epimerase: partial peptide sequences and tissue localization. Biochem Pharmacol 1995;50:1803-1806.
56. Menzel S, Sauernheimer C, Brune K, Geisslinger G: Is the inversion from R- to S-ketoprofen concentration dependent? Investigations in rats in vivo and in vitro. Biochem Pharmacol 1994;47: 1267-1270.
57. Foster RT, Jamali F: Stereoselective pharmacokinetics of ketoprofen in the rat. Drug Metab Dispos 1988;4:623-626.
58. Jamali F, Brocks DR: Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 1990;19:197-217.
59. Jamali F, Berry BW, Tehrani MR, Russell AS: Stereoselective pharmacokinetics of flurbiprofen in humans and rats. J Pharm Sci 1988;77:666-669.
60. Geisslinger G, Lötsch J, Menzel S, Kobal G, Brune K: Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. Br J Clin Pharmacol 1994;37:392-394.
61. Knihinicki RD, Day RO, Graham GG, Williams KM: Stereoselective disposition of ibuprofen and flurbiprofen in rats. Chirality 1990;2:134-140.
62. Menzel-Soglowek S, Geisslinger G, Mollenhauer J, Brune K: Metabolic chiral inversion of 2-arylpropionates in rat H4IIE and human Hep G2 hepatoma cells: relationship to in vivo metabolism. Biochem Pharmacol 1992;43:1487-1492.
63. Geisslinger G, Ferreira SH, Menzel S, Schlott D, Brune K: Antinociceptive actions of R(-)-flurbiprofen-a non-cyclooxygenase inhibiting 2-arylpropionic acid in rats. Life Sci 1994;54:PL 173-177.
64. Malmberg A, Yaksh TL: Antinociception produced by spinal delivery of the S- and R-enantiomers of flurbiprofen in the formalin test. Eur J Pharmacol 1994;256:205-209.
65. Sunshine A, Zighelboim J, Olson N, Laska E: Flurbiprofen. flurbiprofen dextrorotatory component (BTS 24332), and placebo in post episiotomy pain (abstract). Clin Pharmacol Ther 1987;42: 162.
66. Lötsch J, Geisslinger G, Mohammadian P, Brune K, Kobal G: Effects of flurbiprofen enantiomers on pain-related chemosomatosensory evoked potentials in human subjects. Br J Clin Pharmacol 1995;40:339-346.
67. Thürauf N, Hummel T, Kettenmann B, Kobal G: Nociceptive and reflexive responses recorded from the human nasal mucosa. Brain Res 1993;629:293-299.
68. Neugebauer V, Geisslinger G, Rümenapp P, Weiretter F, Szelenyi I, Brune K, Schaible H-G: Antinociceptive effects of R(-)- and S(+)-flurbiprofen on rat spinal dorsal horn neurons rendered hyperexcitable by an acute knee joint inflammation. J Pharmacol Exp Ther 1995;275:618-628.
69. Malmberg A, Yaksh TL: Antinociceptive actions of spinal non-steroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther 1992;263:136-146.
70. McCormack K: Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994;59:9-43.
71. Malmberg A, Yaksh TL: Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats. J Neurosci 1995;15:2768-2776.
72. Breder CD, Smith WL, Raz A, Masferrer JL, Seibert K, Needleman P, Saper CB: The distribution and characterization of cyclooxygenase-like immunoreactivity in the ovine brain. J Comp Neurol 1992;322:409-438.
73. Breder CD, DeWitt D, Kraig RP: Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995;355:296-315.
74. Ramwell PW, Shaw JE, Jessup R: Spontaneous and evoked release of prostaglandins from frog spinal cord. Am J Physiol 1966;211:998-1004.
75. Coderre TJ, Gonzales R, Goldyne ME, West J, Levine JD: Noxious stimulus-induced increase in spinal prostaglandin E2 is noradrenergic terminal-dependent. Neurosci Lett 1990;115:253-256.
76. Yaksh TL: Central and peripheral mechanisms for the analgesic action of acetylsalicylic acid. In. Barett HJM, Hirsh J, Mustard JF (eds.): Acetylsalicylic Acid: New Uses for an Old Drug. New York: Raven Press, 1982;137-151.
77. Geisslinger G, Dietzel K, Loew D, Schuster O, Rau G, Lachmann G, Brune K: High-performance liquid chromatographic determination of ibuprofen, its metabolites and enantiomers in biological fluids. J Chromatogr 1989;491:139-149.
78. Vasco MR, Zirkelbach SL, Waite KJ: Prostaglandins stimulate the release of substance P from rat spinal cord slices. In, Jurna I, Yaksh TL (eds.): Progress in Pharmacology and Clinical Pharmacology. Volume 10. Stuttgart: Fischer Verlag. 1993;69-89.
79. Schorderet M, Straub WR: Effects of non-narcotic analgesics and nonsteroid anti-inflammatory agents upon inorganic phosphates, intracellular potassium and impulse conduction in mammalian nerve fibers. Biochem Pharmacol 1971;20:1355-1361.
80. Biella G, Groppetti A: Correlation between the antinociceptive effect of aspirin and central transmitters. In, Jurna I, Yaksh TL (eds.): Progress in Pharmacology and Clinical Pharmacology. Volume 10. Stuttgart: Fischer Verlag, 1993;1-9.
81. Bensemana D, Gascon AL: Relationship between analgesia and turnover of brain biogenic amines. Can J Phys Pharmacol 1978;56:721-730.
82. Tjolsen A, Lund A, Hole K: Antinociceptive effect of paracetamol in rats is partly dependent on spinal serotoninergic systems. Eur J Pharmacol 1991;193:193-201.
83. Zhao B, Geisslinger G, Hall I, Day RO, Williams KM: The effect of the enantiomers of ibuprofen and flurbiprofen on the β-oxidation of palmitate in the rat. Chirality 1992;4:137-141.
84. Kvamme E, Torgner IA: Phosphate-dependent effects of palmitoyl-CoA and stearyl-CoA on phosphate-activated pig brain and pig kidney glutaminase. FEBS Lett 1974;47:244-247.
85. Wechter WJ, Bigornia AE, Murray ED, Levine BH, Young JW: Rac-flurbiprofen is more ulcerogenic than its (S)-enantiomer. Chirality 1993;5:492-494.